Novo Nordisk Stock Jumps After Earnings. Compounding Market’s Growth Took it By Surprise
In This Article:
The Danish drugmaker now expects sales growth between 13% and 21%, down from a previous range of 16% to 24%.
Oops, something went wrong
The Danish drugmaker now expects sales growth between 13% and 21%, down from a previous range of 16% to 24%.